$290.36 0.9%
AMGN Stock Price vs. AI Score
Data gathered: November 21

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Amgen (AMGN)

Analysis generated November 6, 2024. Powered by Chat GPT.

Amgen Inc., headquartered in Thousand Oaks, California, is one of the world's leading biotechnology companies. It focuses on human therapeutics and has a robust portfolio of products aimed at addressing severe illnesses. The company's approach includes leveraging advances in cellular and molecular biology to generate unique, innovative therapies.

Read full AI stock Analysis

Stock Alerts - Amgen (AMGN)

company logo Amgen | November 15
Price is down by -5% in the last 24h.
company logo Amgen | November 12
Price is down by -5.8% in the last 24h.
company logo Amgen | November 12
Ro Khanna (member of U.S. congress) is buying shares
company logo Amgen | October 9
Web Traffic is up by 53.4% over the last month.

About Amgen

Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.


Amgen
Price $290.36
Target Price Sign up
Volume 1,670,000
Market Cap $150B
Year Range $259.07 - $337.38
Dividend Yield 3.21%
PE Ratio 35.71
Analyst Rating 48% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '248.5B6.14B2.37B2.83B5.08B5.580
Q2 '248.52B6.22B2.3B746M2.8B4.970
Q1 '246.76B6.21B548M-113M1.96B3.960
Q4 '237.63B6.5B1.13B767M2.77B4.710
Q3 '236.33B3.88B2.44B1.73B3.4B4.960

Insider Transactions View All

Grygiel Nancy A. filed to sell 9,883 shares at $313.1.
May 3 '24
Grygiel Nancy A. filed to sell 10,874 shares at $273.
December 4 '23
Graham Jonathan P filed to sell 28,078 shares at $272.8.
November 13 '23
Gordon Murdo filed to sell 44,308 shares at $262.4.
August 11 '23
Khosla Rachna filed to sell 6,630 shares at $292.9.
November 10 '22

What is the Market Cap of Amgen?

The Market Cap of Amgen is $150B.

What is Amgen's PE Ratio?

As of today, Amgen's PE (Price to Earnings) ratio is 35.71.

What is the current stock price of Amgen?

Currently, the price of one share of Amgen stock is $290.36.

How can I analyze the AMGN stock price chart for investment decisions?

The AMGN stock price chart above provides a comprehensive visual representation of Amgen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amgen shares. Our platform offers an up-to-date AMGN stock price chart, along with technical data analysis and alternative data insights.

Does AMGN offer dividends to its shareholders?

Yes, Amgen (AMGN) offers dividends to its shareholders, with a dividend yield of 3.21%. This dividend yield represents Amgen's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Amgen in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.

What are some of the similar stocks of Amgen?

Some of the similar stocks of Amgen are Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.